3.81
price down icon4.99%   -0.20
after-market Handel nachbörslich: 3.62 -0.19 -4.99%
loading
Schlusskurs vom Vortag:
$4.01
Offen:
$3.95
24-Stunden-Volumen:
222.86K
Relative Volume:
0.44
Marktkapitalisierung:
$57.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.616
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
-14.57%
1M Leistung:
-31.10%
6M Leistung:
-76.31%
1J Leistung:
-86.17%
1-Tages-Spanne:
Value
$3.65
$3.95
1-Wochen-Bereich:
Value
$3.65
$4.385
52-Wochen-Spanne:
Value
$3.65
$30.70

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name
Firmenname
Jasper Therapeutics Inc
Name
Telefon
(650) 549-1400
Name
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Name
Mitarbeiter
64
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
JSPR's Discussions on Twitter

Vergleichen Sie JSPR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
JSPR
Jasper Therapeutics Inc
3.81 57.23M 0 -64.47M -52.33M -6.1852
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Eingeleitet UBS Buy
2024-12-06 Eingeleitet BMO Capital Markets Outperform
2024-09-09 Eingeleitet JMP Securities Mkt Outperform
2024-07-08 Eingeleitet BTIG Research Buy
2024-06-27 Eingeleitet Stifel Buy
2024-05-06 Eingeleitet H.C. Wainwright Buy
2024-04-03 Eingeleitet Evercore ISI Outperform
2024-03-28 Eingeleitet RBC Capital Mkts Outperform
2024-03-18 Eingeleitet TD Cowen Outperform
2023-08-11 Eingeleitet CapitalOne Overweight
2022-02-28 Eingeleitet Cantor Fitzgerald Overweight
2021-11-08 Eingeleitet Credit Suisse Outperform
2021-10-21 Eingeleitet William Blair Outperform
2021-10-20 Eingeleitet BMO Capital Markets Outperform
2021-10-13 Eingeleitet Oppenheimer Outperform
Alle ansehen

Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten

pulisher
Apr 02, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 19.7% in March - Defense World

Apr 02, 2025
pulisher
Mar 28, 2025

JSPR stock touches 52-week low at $4.54 amid market challenges By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

JSPR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 26, 2025

Jasper Therapeutics Inc Files For Common Stock Offering Of Up To $100 MillionSEC Filing - MarketScreener

Mar 26, 2025
pulisher
Mar 25, 2025

DBV Technologies (NASDAQ:DBVT) vs. Jasper Therapeutics (NASDAQ:JSPR) Head to Head Comparison - Defense World

Mar 25, 2025
pulisher
Mar 20, 2025

Jasper Therapeutics inks new sales agreement, ends previous deal By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $62.50 - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics inks new sales agreement, ends previous deal - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics Files $300 Million Mixed Shelf -March 19, 2025 at 05:08 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics Signs New Sales Agreement with Jefferies - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics terminates Cantor sales agreement -March 19, 2025 at 04:53 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Jasper Therapeutics files for mixed shelf offering of up to $300 mln -March 19, 2025 at 04:17 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 14, 2025

(JSPR) On The My Stocks Page - news.stocktradersdaily.com

Mar 14, 2025
pulisher
Mar 14, 2025

Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 14, 2025
pulisher
Mar 11, 2025

Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks

Mar 11, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World

Mar 07, 2025
pulisher
Mar 03, 2025

Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study - MSN

Mar 02, 2025
pulisher
Mar 02, 2025

JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 02, 2025
pulisher
Mar 01, 2025

Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq

Mar 01, 2025
pulisher
Mar 01, 2025

Jasper Therapeutics Presents Clinical and Preclinical - GlobeNewswire

Mar 01, 2025
pulisher
Mar 01, 2025

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Yahoo Finance UK

Mar 01, 2025
pulisher
Mar 01, 2025

Can Jasper Therapeutics' Briquilimab Transform Chronic Urticaria Treatment? New Clinical Data Revealed - Stock Titan

Mar 01, 2025
pulisher
Feb 28, 2025

Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics to present briquilimab study at AAD Meeting - Investing.com India

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics to present briquilimab study at AAD Meeting By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics Announces Late-Breaking Briquilimab - GlobeNewswire

Feb 28, 2025
pulisher
Feb 28, 2025

Can Jasper's Briquilimab Data for Chronic Urticaria Transform Treatment Outcomes? - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Jasper Therapeutics Reports Promising Clinical Progress - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Feb 27, 2025
pulisher
Feb 26, 2025

Earnings To Watch: Life Time (LTH) Reports Q4 Results Tomorrow - The Globe and Mail

Feb 26, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics Sets March Conference Circuit to Showcase Mast Cell Disease Breakthroughs - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes CSU stock outlook - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes CSU stock outlook - Investing.com India

Feb 25, 2025
pulisher
Feb 23, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Feb 20, 2025
pulisher
Feb 19, 2025

What To Expect From RE/MAX’s (RMAX) Q4 Earnings - The Globe and Mail

Feb 19, 2025
pulisher
Feb 18, 2025

Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada

Feb 18, 2025
pulisher
Feb 18, 2025

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World

Feb 18, 2025
pulisher
Feb 15, 2025

Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat

Feb 15, 2025

Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):